Literature DB >> 24613868

Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example.

Barbara C Tilley1, Nancy R LaPelle2, Christopher G Goetz3, Glenn T Stebbins3.   

Abstract

BACKGROUND: Cognitive pretesting, a qualitative step in scale development, precedes field testing and assesses the difficulty of instrument completion for examiners and respondents. Cognitive pretesting assesses respondent interest, attention span, discomfort, and comprehension, and highlights problems with the logical structure of questions/response options that can affect understanding. In the past this approach was not consistently used in the development or revision of movement disorders scales.
METHODS: We applied qualitative cognitive pretesting using testing guides in development of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The guides were based on qualitative techniques, verbal probing and "think-aloud" interviewing, to identify problems with the scale from the patient and rater perspectives. English-speaking Parkinson's disease patients and movement disorders specialists (raters) from multiple specialty clinics in the United States, Western Europe and Canada used the MDS-UPDRS and completed the testing guides.
RESULTS: Two rounds of cognitive pretesting were necessary before proceeding to field testing of the revised scale to assess clinimetric properties. Scale revisions based on cognitive pretesting included changes in phrasing, simplification of some questions, and addition of a reassuring statement explaining that not all PD patients experience the symptoms described in the questions.
CONCLUSIONS: The strategy of incorporating cognitive pretesting into scale development and revision provides a model for other movement disorders scales. Cognitive pretesting is being used in translating the MDS-UPDRS into multiple languages to improve comprehension and acceptance and in the development of a new Unified Dyskinesia Rating Scale for Parkinson's disease patients.

Entities:  

Keywords:  Cognitive pretesting; Modified Unified Parkinson's Disease Rating Scale; Parkinson's disease; scale development

Mesh:

Year:  2014        PMID: 24613868      PMCID: PMC5086096          DOI: 10.3233/JPD-130310

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  7 in total

1.  Role of cognitive testing in the development of the CAHPS Hospital Survey.

Authors:  Roger E Levine; Floyd J Fowler; Julie A Brown
Journal:  Health Serv Res       Date:  2005-12       Impact factor: 3.402

2.  Cognitive interviewing in the evaluation of fatigue items: results from the patient-reported outcomes measurement information system (PROMIS).

Authors:  Christopher Christodoulou; Doerte U Junghaenel; Darren A DeWalt; Nan Rothrock; Arthur A Stone
Journal:  Qual Life Res       Date:  2008-10-12       Impact factor: 4.147

3.  Development and preliminary validation of the NePIQoL: a quality-of-life measure for neuropathic pain.

Authors:  Helen M Poole; Peter Murphy; Turo J Nurmikko
Journal:  J Pain Symptom Manage       Date:  2008-08-03       Impact factor: 3.612

4.  Systematic evaluation of rating scales for impairment and disability in Parkinson's disease.

Authors:  Claudia Ramaker; Johan Marinus; Anne Margarethe Stiggelbout; Bob Johannes Van Hilten
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

5.  Development and initial validation of a heart disease knowledge questionnaire for people with rheumatoid arthritis.

Authors:  Holly John; Gareth J Treharne; Elizabeth D Hale; Vasileios F Panoulas; Douglas Carroll; George D Kitas
Journal:  Patient Educ Couns       Date:  2009-04-22

6.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Authors:  Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

7.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

Authors:  Christopher G Goetz; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Glenn T Stebbins; Matthew B Stern; Barbara C Tilley; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J Van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

  7 in total
  7 in total

1.  Cross-Cultural Differences of the Non-Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society- Unified Parkinson's Disease Rating Scale.

Authors:  Rwei-Ling Yu; Ruey-Meei Wu; Anne Y Y Chan; Vincent Mok; Yih-Ru Wu; Barbara C Tilley; Sheng Luo; Lu Wang; Nancy R LaPelle; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord Clin Pract       Date:  2016-04-08

2.  IPMDS-Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the MDS-UPDRS and UDysRS.

Authors:  Christopher G Goetz; Glenn T Stebbins; Lu Wang; Nancy R LaPelle; Sheng Luo; Barbara C Tilley
Journal:  Mov Disord Clin Pract       Date:  2014-05-14

3.  Commonalities and challenges in the development of clinical trial measures in neurology.

Authors:  Jesse M Cedarbaum; Diane Stephenson; Richard Rudick; Maria C Carrillo; Glenn Stebbins; Douglas Kerr; Jill Heemskerk; Wendy R Galpern; Petra Kaufmann; David Cella; Maria Isaac; Marc K Walton
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

4.  Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS).

Authors:  Pablo Martinez-Martin; Anette Schrag; Daniel Weintraub; Alexandra Rizos; Carmen Rodriguez-Blazquez; Kallol Ray Chaudhuri
Journal:  Mov Disord Clin Pract       Date:  2019-02-05

5.  Development and Validation of a Fall Questionnaire for Patients with Parkinson's Disease.

Authors:  Anika Frank; Jonas Bendig; Sophia Finkbeiner; Tom Hähnel; Nils Schnalke; Tim Feige; Heinz Reichmann; Björn H Falkenburger
Journal:  Mov Disord Clin Pract       Date:  2022-07-23

6.  Exploring Willingness of Elder Chinese in Houston to Participate in Clinical Research.

Authors:  Logan R Thornton; Rossybelle P Amorrortu; Daniel W Smith; Arch G Mainous; Sally W Vernon; Barbara C Tilley
Journal:  Contemp Clin Trials Commun       Date:  2016-06-24

7.  Validation Study of the Official Korean Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Authors:  Jinse Park; Seong Beom Koh; Kyum Yil Kwon; Sang Jin Kim; Jae Woo Kim; Joong Seok Kim; Kun Woo Park; Jong Sam Paik; Young H Sohn; Jin Young Ahn; Eungseok Oh; Jinyoung Youn; Ji Young Lee; Phil Hyu Lee; Wooyoung Jang; Han Joon Kim; Beom Seok Jeon; Sun Ju Chung; Jin Whan Cho; Sang Myung Cheon; Suk Yun Kang; Mee Young Park; Seongho Park; Young Eun Huh; Seok Jae Kang; Hee Tae Kim
Journal:  J Clin Neurol       Date:  2020-10       Impact factor: 3.077

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.